A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833
NCT05364255
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
6
Enrollment
INDUSTRY
Sponsor class
Conditions
ER-positive, HER2-negative Breast Cancer
Interventions
DRUG:
[14C]AZD9833 Oral Solution, 75 mg
Sponsor
AstraZeneca
Collaborators
[object Object]